Personalized Evaluation of Biomarker Value: A Cost-Benefit Perspective.

TitlePersonalized Evaluation of Biomarker Value: A Cost-Benefit Perspective.
Publication TypeJournal Article
Year of Publication2016
AuthorsHuang, Ying, and Eric Laber
JournalStat Biosci
Volume8
Pagination43-65
Date Published2016
ISSN1867-1764
Abstract

For a patient who is facing a treatment decision, the added value of information provided by a biomarker depends on the individual patient's expected response to treatment with and without the biomarker, as well as his/her tolerance of disease and treatment harm. However, individualized estimators of the value of a biomarker are lacking. We propose a new graphical tool named the subject-specific expected benefit curve for quantifying the personalized value of a biomarker in aiding a treatment decision. We develop semiparametric estimators for two general settings: (i) when biomarker data are available from a randomized trial; and (ii) when biomarker data are available from a cohort or a cross-sectional study, together with external information about a multiplicative treatment effect. We also develop adaptive bootstrap confidence intervals for consistent inference in the presence of nonregularity. The proposed method is used to evaluate the individualized value of the serum creatinine marker in informing treatment decisions for the prevention of renal artery stenosis.

DOI10.1007/s12561-014-9122-4
Alternate JournalStat Biosci
Original PublicationPersonalized evaluation of biomarker value: A cost-benefit perspective.
PubMed ID27446505
PubMed Central IDPMC4938856
Grant ListP01 CA053996 / CA / NCI NIH HHS / United States
R01 GM106177 / GM / NIGMS NIH HHS / United States
U24 CA086368 / CA / NCI NIH HHS / United States
U01 CA086368 / CA / NCI NIH HHS / United States
R01 GM054438 / GM / NIGMS NIH HHS / United States
S10 OD020069 / OD / NIH HHS / United States
P01 CA142538 / CA / NCI NIH HHS / United States